‘Remarkable’ pancreatic cancer jab offers longer survival hope for patients
Researchers say that a vaccine, which is seen to slow down the progress of one of the most deadly cancers, can be produced collectively.
JAB gave hope to patients after a experiment and increased the survival of the participants. pancreatic cancer.
Researchers described the findings as “remarkable ve and began to test the efficiency of Jab between a larger pancreatic and intestinal cancer group.
JAB uses a new type of immunotherapy designed to improve vaccine transmission to lymph nodes, which helps the body to fight infections and disease.
Pancreatic and intestinal cancers carry a mutation in a gene called Kras, which plays an important role in tumor growth, and scientists develop Jab to recognize and attack this gene.
The study published in the journal Nature Medical20 patients with pancreas cancer and five were tested with bowel cancer.
When the participants were followed after 20 months, 68 percent had developed strong immune reactions specific to mutant kras tumor proteins.
Participants with the most powerful immune reactions lived without cancer for longer than those with weaker responses and remained without cancer.
Some patients survived about two years five months after vaccination.
In contrast, only three out of 10 people diagnosed with pancreas cancer survive for a year.
Pancreatic cancer has some of the worst survival rates due to late detection. It usually does not cause symptoms in early stages and may cause abdominal pain, yellowing of the skin, unexplained weight loss and changes in feces.
Many patients see that their cancers return even after treatments such as radiotherapy and chemotherapy.
However, the trial showed that Jab could help prevent cancer from returning for more than 15 months.
Unlike other personalized cancer jabs for individual patients, this vaccine ELI-002 2P has a single version that can be given to all patients, ie it can be produced collectively and can be given faster.
Cancer Research UK Research Information Manager Dani Edmunds said: “Vaccines can help people with pancreas and intestinal cancer to live longer than cancer.”
“We can be sure that some people take advantage of the vaccine, we can be sure that we eat cancer for others,” he added.
Professor Richard Sullivan, Director of Conflict and Health Research Center at King’s College London, suggested that more research is needed.
“There are some interesting sciences in this study, but this is a long way to prove any clinical benefit,” he said.
